Lumos Pharma, Inc. Announces Resignation of Eugene P. Kennedy as Chief Medical Officer, Effective March 6, 2021
February 09, 2021 at 03:35 am IST
Share
On February 4, 2021, Eugene P. Kennedy, M.D. notified Lumos Pharma, Inc. that he would be resigning from his position as the Company's Chief Medical Officer effective March 6, 2021 to assume a position with another company focusing on oncology. The Company wishes Dr. Kennedy well and has initiated a search for Dr. Kennedy's successor.
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.
LUMOS PHARMA, INC. 
